fc and fcr in cll and indolent nhl a descriptive retrospective institutional study
Download
Skip this Video
Download Presentation
FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study

Loading in 2 Seconds...

play fullscreen
1 / 17

FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study - PowerPoint PPT Presentation


  • 101 Views
  • Uploaded on

FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study. Aftimos P, Chahine G Hotel-Dieu de France University Hospital Beirut, Lebanon. LSMO 7: National Forum Le Royal, Dbaye 11/14/2008. Indolent NHL: Standard Approaches. Watch and Wait (worry)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study' - rock


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
fc and fcr in cll and indolent nhl a descriptive retrospective institutional study

FC and FCR in CLL and Indolent NHL: A descriptive retrospective institutional study

Aftimos P, Chahine G

Hotel-Dieu de France University Hospital

Beirut, Lebanon

LSMO 7: National Forum

Le Royal, Dbaye

11/14/2008

indolent nhl standard approaches
Indolent NHL: Standard Approaches
  • Watch and Wait (worry)
  • Alkylating agents ± steroids
  • CVP
  • CHOP
  • Fludara
  • Fludara combination chemo
  • “New and improved” biological therapies
objective
OBJECTIVE
  • The purpose of this study is to evaluate the results of treatment of indolent NHL and CLL by FC and FCR.
material and methods
MATERIAL AND METHODS
  • Descriptive, retrospective study
  • Patients with CLL or indolent lymphomas treated by FC or FCR between 1998 and 2004
  • Overall survival (OS) and disease-free interval (DFI) have been calculated, and response to treatment registered
results
RESULTS
  • 43 patients, 33 treated by FC and 10 by FCR
  • 26 (60%) ♀ ; 17 (40%) ♂
  • Mean age = 62.07 years old
  • Median age = 61 years old
  • 53.5% treated first line
  • 23.3% received Rituximab
flipi index
FLIPI index

Solal-Celigny et al. Blood 2004

prognostic factors
Prognostic Factors
  • B signs: 79% of patients
  • Bone marrow infiltration: 70% of patients
  • Bulky disease: 18.6% of patients
  • Mean LDH = 775 (Nl: 313-618). 40% elevated
  • 57% above 60 years old
  • 79.1% stage III or IV
survival
Survival
  • Relapse rate = 51.2%
  • DFI = 20 months
  • Overall survival:
  • 85% at 1 year
  • 68% at 3 years
  • 55% at 5 years
conclusion
CONCLUSION
  • Epidemiology, patient and disease characteristics from our series concur with the published data
  • The first FCR paper published by MD Anderson* showed a RR of 95% (CR = 70%). All patients received Rituximab and were treated upfront. They were younger and had less advanced disease
  • Update of our series is expected in 2009 with almost 100 patients and uniform administration of Rituximab

* J Clin Oncol 2005;23(18):4079-88

ad